HGF mimetic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Because 10 to 30 percent of older people may be unable to effectively absorb vitamin B12 naturally occurring in foods, those older than 50 years should meet their RDA mainly by consuming foods fortified with vitamin B12 or a supplement containing vitamin B12. As for safety, tolerable upper intake levels (known as ULs) are set for vitamins and minerals when evidence is sufficient. In the case of vitamin B12 there is no UL, as there is no human data for adverse effects from high doses. Collectively the EARs, RDAs, AIs, and ULs are referred to as dietary reference intakes (DRIs). The European Food Safety Authority (EFSA) refers to the collective set of information as "dietary reference values", with population reference intake (PRI) instead of RDA, and average requirement instead of EAR. AI and UL are defined by EFSA the same as in the United States. For women and men over age 18, the adequate intake (AI) is set at 4.0 μg/day. AI for pregnancy is 4.5 μg/day, and for lactation 5.0 μg/day. For children aged 1–14 years, the AIs increase with age from 1.5 to 3.5 μg/day. These AIs are higher than the U.S. RDAs. The EFSA also reviewed the safety question and reached the same conclusion as in the United States—that there was not sufficient evidence to set a UL for vitamin B12. The Japan National Institute of Health and Nutrition set the RDA for people ages 12 and older at 2.4 μg/day. The World Health Organization also uses 2.4 μg/day as the adult recommended nutrient intake for this vitamin. For U.S.
At microwave frequencies, the first, imperfect invisibility cloak was realized in 2006. From the standpoint of governing equations, contemporary researchers can classify the realm of metamaterials into three primary branches: Electromagnetic/Optical wave metamaterials, other wave metamaterials, and diffusion metamaterials. These branches are characterized by their respective governing equations, which include Maxwell's equations (a wave equation describing transverse waves), other wave equations (for longitudinal and transverse waves), and diffusion equations (pertaining to diffusion processes). Crafted to govern a range of diffusion activities, diffusion metamaterials prioritize diffusion length as their central metric. This crucial parameter experiences temporal fluctuations while remaining immune to frequency variations. In contrast, wave metamaterials, designed to adjust various wave propagation paths, consider the wavelength of incoming waves as their essential metric. This wavelength remains constant over time, though it adjusts with frequency alterations. Fundamentally, the key metrics for diffusion and wave metamaterials present a stark divergence, underscoring a distinct complementary relationship between them. For comprehensive information, refer to Section I.B, "Evolution of metamaterial physics," in Ref.
== Professional societies == American Ceramic Society ASM International Association for Iron and Steel Technology Materials Research Society The Minerals, Metals & Materials Society Institute of Materials, Minerals and Mining, UK
===== Supplemental Offer and Acceptance Program ===== The Supplemental Offer and Acceptance Program (SOAP) is a process for partially matched and fully unmatched applicant through the Match. Previous to the creation of SOAP, applicants were given the opportunity to contact the programs about the open positions in a process informally called "the scramble". This frantic, loosely structured system forced soon-to-be medical school graduates to choose within minutes programs not on their original Match list. In 2012, the NRMP introduced the organized system called SOAP. As part of the transition, Match Day was also moved from the third Thursday in March to the third Friday. The SOAP occurs during Match Week. First the applicants eligible for SOAP, are informed they did not secure a Match position on the Monday of Match Week. The locations of remaining unfilled residency positions are released to the unmatched applicants the following day. Then programs contact applicants for interviews that usually occur via phone calls. After that, programs prepare lists of applicants and the positions open are offered by each program one at a time to the top applicant on their list. The applicant may accept the offer or reject it. If the offer is rejected it will go to the next applicant in the program list during the next round of SOAP. During Match year 2021 there were four rounds of SOAP.
The formation of the peptide bond consumes energy, which, in organisms, is derived from ATP. Peptides and proteins are chains of amino acids held together by peptide bonds (and sometimes by a few isopeptide bonds). Organisms use enzymes to produce nonribosomal peptides, and ribosomes to produce proteins via reactions that differ in details from dehydration synthesis. Some peptides, like alpha-amanitin, are called ribosomal peptides as they are made by ribosomes, but many are nonribosomal peptides as they are synthesized by specialized enzymes rather than ribosomes. For example, the tripeptide glutathione is synthesized in two steps from free amino acids, by two enzymes: glutamate–cysteine ligase (forms an isopeptide bond, which is not a peptide bond) and glutathione synthetase (forms a peptide bond).
Sources: en.wikipedia.org
=== Dissolving microneedles === Dissolving MNs are mostly composed of water-soluble drugs that enable the dissolution of MN tips when inserted into skin. This is a one-step approach which does not require the removal of MNs and is convenient for long-term therapy. However, incomplete insertion and delay dissolution is observed with the use of dissolving MNs. This polymer would allow the drug to be delivered into the skin and could be broken down once inside the body. Pharmaceutical companies and researchers have begun to study and implement polymers such as Fibroin, a silk-based protein that can be molded into structures like microneedles and dissolved once in the body.
Melanocytes and basal cells are embedded in the epidermal layer. Upon exposure to UVB rays, melanocytes will produce more melanin, a pigment that gives skin its color. UVB can cause the formation of freckles and dark spots, both of which are symptoms of photoaging; these are most common in people with fair or light skin. With frequent long-term exposure to UVB rays, signs of photoaging might appear, and precancerous lesions or skin cancer may develop as well as damage to DNA. UVA rays are able to penetrate deeper into the skin than UVB rays, damaging the dermal layer as well as the epidermal layer. The dermis is the second major layer of the skin, and it comprises collagen, elastin, and extrafibrillar matrix, which provides structural support to the skin. With chronic UVA exposure, damage to dermal collagen, elastin, and the extracellular matrix contributes to skin laxity, roughness, and wrinkling. Due to the presence of blood vessels in the dermis, UVA rays can lead to dilated or broken blood vessels, which are most commonly visible on the nose and cheeks. UVA can also damage DNA indirectly through the generation of reactive oxygen species (ROS), which include superoxide anion, peroxide, and singlet oxygen. These ROS damage cellular DNA as well as lipids and proteins.
=== Chemical === Rutherfordium is the first transactinide element and the second member of the 6d series of transition metals. Calculations on its ionization potentials, atomic radius, as well as radii, orbital energies, and ground levels of its ionized states are similar to that of hafnium and very different from that of lead. Therefore, it was concluded that rutherfordium's basic properties will resemble those of other group 4 elements: titanium, zirconium, and hafnium. Some of its properties were determined by gas-phase experiments and aqueous chemistry. The oxidation state +4 is the only stable state for the latter two elements, so rutherfordium should also exhibit a stable +4 state. Rutherfordium is also expected to be able to form a less stable +3 state. The standard reduction potential of the Rf4+/Rf couple is predicted to be higher than −1.7 V. Initial predictions of the chemical properties of rutherfordium were based on calculations which indicated that the relativistic effects on the electron shell might be strong enough that the 7p orbitals would have a lower energy level than the 6d orbitals, giving it a valence electron configuration of 6d1 7s2 7p1 or even 7s2 7p2, making the element behave more like lead than hafnium. With better calculation methods and experimental studies of the chemical properties of rutherfordium compounds, it could be shown that this does not happen and that rutherfordium instead behaves like the other group 4 elements.
On 26 September, Trump rejected Iran's seven-day ceasefire proposal and expressed doubt that Tehran would eventually comply with his administration's nuclear demands. In a phone interview the following day, Trump said that he still expected more talks with Iran to resume during the week. Trump claimed that Iran "wanted to make a deal," but they "overplayed their hand" by offering conditions that the US "would have maybe agreed to a year ago." By late September 2026, crude oil and petroleum flows through the Strait of Hormuz had recovered to 77% to 80% of pre-war levels, totaling an estimated 13.19 million barrels per day. A US Navy campaign that used armed convoy escorts and unmonitored "dark transits" was responsible for the stabilization of shipping traffic. Iran's own oil and petrochemical exports were severely limited at the same time due to the combined effects of an active US naval blockade and a broad secondary sanctions campaign known as Operation Economic Outcast. This economic contraction drove the Iranian rial to a historic low of 2.5 million rials per U.S. dollar, significantly eroding Iran's primary geopolitical leverage against Washington. Despite the decline in its conventional enforcement capabilities, the IRGC maintained asymmetric tactics, ensuring maritime insurance premiums remained highly elevated. As worries about Iranian retaliation grew, the US military sent two more Patriot missile batteries to Saudi Arabia and Qatar in September 2026 to safeguard vital energy infrastructure.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.